The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 24, 2020
Filed:
Feb. 17, 2017
Applicant:
Acea Biosciences Inc., San Diego, CA (US);
Inventors:
Xiao Xu, San Diego, CA (US);
Xiaobo Wang, San Diego, CA (US);
Long Mao, San Diego, CA (US);
Li Zhao, San Diego, CA (US);
Biao Xi, San Diego, CA (US);
Assignee:
ACEA THERAPEUTICS, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); C07D 487/04 (2006.01); A61K 31/52 (2006.01); A61K 31/506 (2006.01); C07D 473/32 (2006.01); C07D 401/14 (2006.01); C07D 473/34 (2006.01); C07D 403/12 (2006.01); C07D 239/46 (2006.01); C07D 239/42 (2006.01); C07D 239/47 (2006.01); C07D 473/40 (2006.01); C07D 487/02 (2006.01); C07D 401/12 (2006.01); C07D 239/48 (2006.01); C07D 473/16 (2006.01); C07D 473/24 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 31/506 (2013.01); A61K 31/52 (2013.01); A61K 45/06 (2013.01); C07D 239/42 (2013.01); C07D 239/46 (2013.01); C07D 239/47 (2013.01); C07D 239/48 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 473/16 (2013.01); C07D 473/24 (2013.01); C07D 473/32 (2013.01); C07D 473/34 (2013.01); C07D 473/40 (2013.01); C07D 487/02 (2013.01); C07D 487/04 (2013.01);
Abstract
The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.